N Engl J Med 2022; 386: 449-462.
Normal View Dyslexic View
Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma.
1 March 2022
Randomized clinical trials Upper GI
N Engl J Med 2022; 386: 449-462.
A total of 970 patients with advanced oesophageal cancer were studied. The addition of nivolumab with, or without ipilimumab, to standard chemotherapy improved median survival: 13.2 months nivolumab with chemotherapy; 12.7 months with additional ipilimumab; 10.7 months chemotherapy alone. Survival was improved in tumours with PD-L1 expression of one percent or greater.
Published on: 1 March 2022
Article ID: rct229


.png)





.jpg)
